A retrospective chart review of Auryxia® (ferric citrate) in chronic kidney disease (CKD) patients on dialysis.

Trial Profile

A retrospective chart review of Auryxia® (ferric citrate) in chronic kidney disease (CKD) patients on dialysis.

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Dec 2016

At a glance

  • Drugs Ferric citrate (Primary)
  • Indications Hyperphosphataemia; Kidney disorders
  • Focus Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 01 Dec 2016 New trial record
    • 18 Nov 2016 Results published in the Keryx Biopharmaceuticals Media Release
    • 18 Nov 2016 Data from this study presented at the American Society of Nephrologys 2016 Kidney Week, as reported by a Keryx Biopharmaceuticals Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top